Lupin receives USFDA approval for generic Corgard Tablets

10 Oct 2017 Evaluate

Lupin has received final approval for its Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg from the United States Food and Drug Administration (USFDA) to market a generic version of US WorldMeds, LLC’s Corgard Tablets, 20 mg, 40 mg, and 80 mg.

Lupin’s Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg are the AB rated generic equivalent of US WorldMeds, LLC’s Corgard Tablets, 20 mg, 40 mg, and 80 mg. They are indicated for management of patients with angina pectoris and for the treatment of hypertension. Nadolol Tablets USP, 20 mg, 40 mg, and 80 mg Tablets had annual sales of approximately $109.8 million in the US, as per IMS MAT June 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×